Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral THU-decitabine in Advanced Myeloproliferative Neoplasms
NCT07872709Phase 2Not yet recruiting
- Sponsor
- John Mascarenhas
- Start
- Jan 2027
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of tetrahydrouridine, decitabine in Myeloproliferative Neoplasm (MPN), myelofibrosis (MF), sponsored by John Mascarenhas. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
tetrahydrouridinedecitabine
03
Conditions
Myeloproliferative Neoplasm (MPN)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07872709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07872709.